BioGaia AB (publ) (BIOGB) Earnings Call Transcripts

BioGaia AB (publ)'s Latest Earnings Call - Q1 FY2026

In Q1 2026, BioGaia AB reported net sales of SEK 373 million, reflecting a 2% increase year-over-year, with organic growth of 15% when excluding currency effects. The company's EBIT margin remained stable at 27%, with operating profit rising 4% to SEK 101 million. Management maintained a positive outlook, emphasizing strong performance in direct markets and the successful rollout of new products, including the next-generation BioGaia Protectis Plus. No changes to guidance were indicated, but management signaled confidence in sustaining double-digit growth across key regions.

Reported metrics

Guidance from management

Management maintained its commitment to improve margins throughout 2026, focusing on cost control and increased sales. No specific numerical guidance was provided.

What management said

For the U.S., we need to get what's called GRAS Approval for a new strain. So that process is starting, and we can't really predict exactly how long that takes. It depends on the review by the regulatory authorities.

So it has been launched thus far in 12 countries. So there will be more markets that will be coming through. We don't specifically announce which markets when because it all depends on registrations and regulatory requirements. We have launched it, though, already in some of our bigger markets, such as the U.S. and Canada. And we have pending to launch it in some of the European markets. So we will be launching it up...

What analysts pressed on

Analysts expressed concerns regarding the sustainability of gross margins given the currency effects and product mix. There were also questions about potential cannibalization of existing products due to new launches.

Main topics on the call

• Strong Organic Growth — BioGaia achieved organic growth of 15% in Q1 2026, with a net sales increase to SEK 373 million. CEO Theresa Agnew noted, "We are happy to report that both our Pediatrics segment and our Adult segment grew double digits....
• Stable EBIT Margin — The EBIT margin was reported at 27%, consistent with the same quarter last year. CFO Alexander Kotsinas stated, "We are still committed to improve our margin during this year," indicating a focus on cost control and incr...
• Product Launch Success — The rollout of new products, particularly Gastrus Pure Action and Protectis Plus, has been a key driver of growth. Agnew mentioned, "This new strain also has higher production levels of anti-inflammatory compounds," high...
• Regional Performance Variability — EMEA saw a significant 24% growth, while Asia-Pacific grew by 6%. Agnew noted, "We had some order variability in China in the quarter," indicating potential challenges in that market.

Read the full BioGaia AB (publ) transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 25 BioGaia AB (publ) earnings call transcripts on record, spanning February 6, 2020 to July 17, 2026. Based on this history, BioGaia AB (publ) reports quarterly. The most recent call on file is dated July 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BIOGB

Exchange

OM

Country

SE

Sector

Health Care

Industry

Biotechnology

Calls on record

25

First call

February 6, 2020

Most recent

July 17, 2026

Reporting cadence

quarterly